Name | No. | For Patients with | Purpose |
---|---|---|---|
PACE-NODES | 23-01 | High risk localised prostate cancer, deemed suitable for SBRT radiotherapy and planned for 12 – 36 months androgen deprivation therapy |
This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer. |
DSSG Group: Genitourinary
LIAM Mc Trial
Name | No. | For Patients with | Purpose |
---|---|---|---|
LIAM Mc Trial | 23-18 | Advanced / metastatic genitourinary cancer (including prostate, kidney, urothelial tract, testicular and/or penile cancers) |
To evaluate the feasibility of introducing a men’s cancer survivorship program into routine follow up care in patients with advanced genitourinary malignancies. |
PEACE 6 – Vulnerable
Name | No. | For Patients with | Purpose |
---|---|---|---|
PEACE 6 – Vulnerable | 20-32 | Castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors |
The purpose of the trial is to evaluate the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability. |
MK3475-905 (KEYNOTE-905)
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK3475-905 (KEYNOTE-905) | 20-16 | Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer |
To Evaluate Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer |
SABRE
Name | No. | For Patients with | Purpose |
---|---|---|---|
SABRE | 22-11 | Prostate Cancer being Treated with Stereotactic Body Radiotherapy |
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer. |
MK3475-365
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK3475-365 | 21-20 | Metastatic Castrate Resistant Prostate Cancer (mCRPC). |
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). |
IMvigor011 B042843
Name | No. | For Patients with | Purpose |
---|---|---|---|
IMvigor011 B042843 | 21-38 | High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011) |
The purpose of this trial is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy. |
IRONMAN: International Registry for Men with Advanced Prostate Cancer
Name | No. | For Patients with | Purpose |
---|---|---|---|
IRONMAN: International Registry for Men with Advanced Prostate Cancer | CTRIAL-IE 17-30 | Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC) |
The purpose of this study is to create an international, population-based, |